JP2013544816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544816A5 JP2013544816A5 JP2013540054A JP2013540054A JP2013544816A5 JP 2013544816 A5 JP2013544816 A5 JP 2013544816A5 JP 2013540054 A JP2013540054 A JP 2013540054A JP 2013540054 A JP2013540054 A JP 2013540054A JP 2013544816 A5 JP2013544816 A5 JP 2013544816A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- mammal
- tlr7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 7
- 230000003042 antagnostic Effects 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 229920000272 Oligonucleotide Polymers 0.000 claims 5
- 102100006355 TLR7 Human genes 0.000 claims 5
- 101700075266 TLR7 Proteins 0.000 claims 5
- 102100016391 TLR9 Human genes 0.000 claims 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 108020000411 toll-like receptors Proteins 0.000 claims 5
- 102000002689 toll-like receptors Human genes 0.000 claims 5
- 229960005486 vaccines Drugs 0.000 claims 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 4
- 108010041986 DNA Vaccines Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 230000000240 adjuvant Effects 0.000 claims 4
- 230000002009 allergen Effects 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 230000003115 biocidal Effects 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 238000001415 gene therapy Methods 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 3
- 229920001914 Ribonucleotide Polymers 0.000 claims 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- -1 allergens Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 229940079866 intestinal antibiotics Drugs 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000002336 ribonucleotide Substances 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 229940012356 Eye Drops Drugs 0.000 claims 2
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 claims 2
- 229940051866 Mouthwash Drugs 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 239000007933 dermal patch Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 239000002324 mouth wash Substances 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 230000000699 topical Effects 0.000 claims 2
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 208000007502 Anemia Diseases 0.000 claims 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 208000002741 Leukoplakia Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039722 Scoliosis Diseases 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 206010043207 Temporal arteritis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000004384 alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41549410P | 2010-11-19 | 2010-11-19 | |
| US61/415,494 | 2010-11-19 | ||
| US201161511709P | 2011-07-26 | 2011-07-26 | |
| US61/511,709 | 2011-07-26 | ||
| PCT/US2011/061412 WO2012068470A2 (en) | 2010-11-19 | 2011-11-18 | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544816A JP2013544816A (ja) | 2013-12-19 |
| JP2013544816A5 true JP2013544816A5 (zh) | 2015-02-26 |
| JP5813778B2 JP5813778B2 (ja) | 2015-11-17 |
Family
ID=46064566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540054A Expired - Fee Related JP5813778B2 (ja) | 2010-11-19 | 2011-11-18 | トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US8486908B2 (zh) |
| EP (2) | EP3213770B1 (zh) |
| JP (1) | JP5813778B2 (zh) |
| KR (2) | KR101985382B1 (zh) |
| CN (2) | CN107012149A (zh) |
| AU (4) | AU2011329668B2 (zh) |
| CA (1) | CA2817891C (zh) |
| ES (1) | ES2697606T3 (zh) |
| MX (1) | MX340363B (zh) |
| WO (1) | WO2012068470A2 (zh) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4874801B2 (ja) * | 2003-06-11 | 2012-02-15 | イデラ ファーマシューティカルズ インコーポレイテッド | 安定化免疫調節オリゴヌクレオチド |
| JP5863670B2 (ja) | 2010-01-19 | 2016-02-17 | ノースウェスタン ユニバーシティ | 核酸および／または他の構成要素を含有している合成ナノ構造体 |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3213770B1 (en) * | 2010-11-19 | 2021-02-24 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
| CN103880941B (zh) * | 2012-12-21 | 2016-02-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| BR112015016420B1 (pt) * | 2013-01-08 | 2022-12-06 | Idera Pharmaceuticals, Inc | Composto de oligonucleotídeo imunorregulatório, composição farmacêutica e uso do composto iro ou da composição farmacêutica |
| EP2754714A1 (en) * | 2013-01-14 | 2014-07-16 | Sarepta Therapeutics, Inc. | Inhibitory oligonucleotides and their use in therapy |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CN104098681B (zh) * | 2013-04-03 | 2016-08-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN104098671A (zh) * | 2013-04-03 | 2014-10-15 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN104098685B (zh) * | 2013-04-03 | 2016-03-23 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB2514591A (en) | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2932122C (en) | 2013-12-03 | 2022-04-19 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| CR20170181A (es) | 2014-10-06 | 2017-05-31 | Exicure Inc | Compuestos anti-tnf |
| WO2016130832A1 (en) | 2015-02-13 | 2016-08-18 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
| WO2016149323A1 (en) * | 2015-03-16 | 2016-09-22 | Exicure, Inc. | Immunomodulatory spherical nucleic acids |
| CN105597079A (zh) * | 2016-01-11 | 2016-05-25 | 中国人民解放军第三军医大学第一附属医院 | 用于治疗银屑病的药物 |
| CN105541947A (zh) * | 2016-01-11 | 2016-05-04 | 中国人民解放军第三军医大学第一附属医院 | 拮抗tlr7/8及tlr9活化的药物分子及用途 |
| AU2017277647B2 (en) * | 2016-06-08 | 2023-07-27 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| EP3533451B1 (en) | 2017-01-21 | 2022-07-27 | Guangzhou Hanfang Pharmaceuticals Co., Ltd. | Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome |
| KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
| JP2021502381A (ja) | 2017-11-08 | 2021-01-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ウイルスベクター誘発性炎症反応を阻害するための組成物および方法 |
| CN113811312A (zh) * | 2019-01-08 | 2021-12-17 | 阿伏伽德罗开发公司 | 脂肪性肝病的治疗 |
| CA3223577A1 (en) * | 2021-06-22 | 2022-12-29 | University Of Massachusetts | Oligonucleotides for ifn-.gamma. signaling pathway modulation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| US6476000B1 (en) | 1999-08-13 | 2002-11-05 | Hybridon, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US6899891B2 (en) | 1999-12-16 | 2005-05-31 | Harry J. Siskind | Nutritional composition, methods of producing said composition and methods of using said composition |
| US6815429B2 (en) | 2000-01-26 | 2004-11-09 | Hybridon, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7115579B2 (en) | 2000-05-01 | 2006-10-03 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| PL1794174T3 (pl) | 2004-09-01 | 2012-11-30 | Dynavax Tech Corp | Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności |
| WO2006063072A2 (en) | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
| AU2005316503A1 (en) | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| US8383598B2 (en) | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8399423B2 (en) | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8426375B2 (en) | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| KR101455081B1 (ko) | 2005-10-12 | 2014-10-27 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨―유사 수용체 기초 면역 반응을 조절하기 위한 면역조절 올리고누클레오티드 (ｉｒｏ) |
| PT1957647E (pt) * | 2005-11-25 | 2015-06-01 | Zoetis Belgium S A | Oligorribonucleótidos imunoestimulantes |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| JP2010536787A (ja) | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様受容体モジュレータ |
| AU2008317261B2 (en) | 2007-10-26 | 2015-04-09 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| US20090131512A1 (en) * | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
| WO2009154609A1 (en) * | 2008-06-17 | 2009-12-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| JP2012505221A (ja) | 2008-10-06 | 2012-03-01 | イデラ ファーマシューティカルズ インコーポレイテッド | 高コレステロール血症および高脂血症ならびにそれらに関連する疾患の予防および処置におけるトル様受容体の阻害剤の使用 |
| JP6275380B2 (ja) | 2009-06-01 | 2018-02-07 | イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｔｌｒ７およびｔｌｒ９の免疫調節オリゴヌクレオチド（ｉｒｏ）アンタゴニストによる自己免疫および炎症性疾患治療の強化 |
| WO2011005942A2 (en) | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
| EP3213770B1 (en) * | 2010-11-19 | 2021-02-24 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
-
2011
- 2011-11-18 EP EP17166068.1A patent/EP3213770B1/en active Active
- 2011-11-18 MX MX2013005667A patent/MX340363B/es active IP Right Grant
- 2011-11-18 CN CN201710061331.XA patent/CN107012149A/zh active Pending
- 2011-11-18 JP JP2013540054A patent/JP5813778B2/ja not_active Expired - Fee Related
- 2011-11-18 ES ES11841875T patent/ES2697606T3/es active Active
- 2011-11-18 KR KR1020137015717A patent/KR101985382B1/ko active IP Right Grant
- 2011-11-18 AU AU2011329668A patent/AU2011329668B2/en not_active Ceased
- 2011-11-18 CN CN2011800558686A patent/CN103415302A/zh active Pending
- 2011-11-18 CA CA2817891A patent/CA2817891C/en active Active
- 2011-11-18 WO PCT/US2011/061412 patent/WO2012068470A2/en active Application Filing
- 2011-11-18 EP EP11841875.5A patent/EP2640420B1/en active Active
- 2011-11-18 US US13/299,555 patent/US8486908B2/en active Active
- 2011-11-18 KR KR1020197015310A patent/KR102100110B1/ko active IP Right Grant
-
2013
- 2013-05-30 US US13/905,242 patent/US9096858B2/en active Active
-
2015
- 2015-07-06 US US14/791,749 patent/US9540651B2/en active Active
-
2016
- 2016-10-26 AU AU2016250372A patent/AU2016250372B2/en not_active Ceased
- 2016-12-01 US US15/366,509 patent/US20170233741A1/en not_active Abandoned
-
2017
- 2017-10-06 US US15/726,805 patent/US20180023085A1/en not_active Abandoned
-
2018
- 2018-07-04 AU AU2018204878A patent/AU2018204878A1/en not_active Abandoned
-
2020
- 2020-04-29 AU AU2020202827A patent/AU2020202827B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544816A5 (zh) | ||
| US11534452B2 (en) | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection | |
| US11549110B2 (en) | Modified short interfering nucleic acid (siNA) molecules and uses thereof | |
| Patel et al. | Novel drugs targeting Toll-like receptors for antiviral therapy | |
| US11472826B2 (en) | Acyclic antivirals | |
| US9617547B2 (en) | Chiral nucleic acid adjuvant | |
| US20170016000A1 (en) | Compositions and agents against hepatitis b virus and uses thereof | |
| Gane | Future anti‐HBV strategies | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| US9133458B2 (en) | Methods for the treatment of hepatitis B and hepatitis D infections | |
| Tao et al. | Present and future therapies for chronic hepatitis B | |
| JP2017538679A5 (zh) | ||
| JP2009515823A5 (zh) | ||
| TW200914033A (en) | Combination motif immune stimulatory oligonucleotides with improved activity | |
| JP2013507933A (ja) | Ｈｂｖアンチセンス阻害剤 | |
| JP2015528449A5 (zh) | ||
| JP2012528867A5 (zh) | ||
| JP2012528867A (ja) | Ｔｌｒ７およびｔｌｒ９の免疫調節オリゴヌクレオチド（ｉｒｏ）アンタゴニストによる自己免疫および炎症性疾患治療の強化 | |
| JP2018512428A5 (zh) | ||
| US11685921B2 (en) | Molecules and agents for treating hepatitis B virus | |
| JP2016510213A5 (zh) | ||
| US10273484B2 (en) | Double-stranded RNA conjugates and their use | |
| EP3436066A1 (en) | Fc receptor-mediated drug delivery | |
| US9872895B2 (en) | TLR5 ligands, therapeutic methods, and compositions related thereto | |
| JP2012508013A (ja) | アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体５発現の調節 |